Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Countries and organisations
Explore psilocybin trials by country, sponsor and research facility. Compare registry status, study-start trends, conditions and mapped research sites.
Free access · No subscription for research tools or data exports
Explore registry geography and organisations
4 trials match this view; 4 mapped facilities. Latest indexed registry check Oct 9, 2026 01:24 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.
Enrollment sum: 97 across 4 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.
Recorded study-start years
Current indexed registry status
Reported research conditions
Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.
Countries with reported trial locations
Sponsors recorded in this index
Matching trial records
| Trial | Sponsor and phase | Status | Enrollment | Start / primary completion / completion | Research workflow |
|---|---|---|---|---|---|
| Psilocybin in the Treatment of Methamphetamine Use DisorderMethamphetamine Use Disorder | Peter Hendricks PHASE2 | Not yet recruiting Registry updated 2026-09-21 | 42 ESTIMATED | 2027-02-01 2032-02-01 2032-02-01 | |
| Psilocybin Recovery Intervention for Stopping Methamphetamine UseMethamphetamine Use Disorder · Human Immunodeficiency Virus (HIV) | Nicky Mehtani, MD, MPH PHASE2 | Not yet recruiting Registry updated 2026-08-11 | 30 ESTIMATED | 2026-11 2029-04 2029-06 | |
| Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based SampleMethamphetamine Use Disorder · Substance-Related Disorders · Chemically-Induced Disorders · Substance Use Disorders · Stimulant-Use Disorder | University of Wisconsin, Madison PHASE1 | Terminated Registry updated 2026-05-12 | 5 ACTUAL | 2023-03-03 2024-03-07 2024-03-07 | |
| A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From MethamphetamineMethamphetamine Use Disorder | Kevin Murnane EARLY_PHASE1 | Recruiting Registry updated 2025-10-07 | 20 ESTIMATED | 2025-04-04 2027-03 2027-03 |
Reported research facilities
University of Alabama at BirminghamBirmingham, Alabama, United States
UCSF at Zuckerberg San Francisco General HospitalSan Francisco, California, United States
University of WisconsinMadison, Wisconsin, United States
LSU Health ShreveportShreveport, Louisiana, United States
This list includes mapped sites of matching trials, including international sites; locations without usable coordinates are omitted. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.